Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

India-based Biocon Limited Establishes Cranbury, New Jersey, Production Operations

09/19/2025
India-based biopharmaceutical company Biocon Limited, through its wholly owned subsidiary Biocon Generics Inc., has established manufacturing operations in Cranbury, New Jersey.

The $30 million project includes the acquisition of the Oral Solid Dosage facility from Eywa Pharma Inc.

“We were deeply honoured to have Governor Phil Murphy and our Chairperson, Kiran Mazumdar-Shaw, join us in marking this milestone of the Biocon Group’s first manufacturing facility in the U.S.,” said Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd. This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide.”

Biocon Limited develops and manufactures biopharmaceuticals, including biosimilars, for chronic diseases like diabetes, cancer, and autoimmune disorders. The company’s key areas include biosimilar insulins, monoclonal antibodies for cancer and immunology, and recombinant proteins.

“We are incredibly grateful that Biocon has decided to open its first U.S. manufacturing facility in the Garden State,” noted Governor Phil Murphy. “For years, Biocon has provided high-quality medicines and treatments to millions of patients across the globe. This state-of-the-art facility marks a significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world.”

Exclusive Research